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Abstract
Background: Plasmodium vivax is responsible for a significant proportion of malaria cases worldwide and is increasingly
reported as a cause of severe disease. The objective of this study was to characterize severe vivax disease among children
hospitalized in intensive care units (ICUs) in the Western Brazilian Amazon, and to identify risk factors associated with
disease severity.
Methods and Findings: In this retrospective study, clinical records of 34 children, 0–14 years of age hospitalized in the 11
public pediatric and neonatal ICUs of the Manaus area, were reviewed. P. falciparum monoinfection or P. falciparum/P. vivax
mixed infection was diagnosed by microscopy in 10 cases, while P. vivax monoinfection was confirmed in the remaining 24
cases. Two of the 24 patients with P. vivax monoinfection died. Respiratory distress, shock and severe anemia were the most
frequent complications associated with P. vivax infection. Ninety-one children hospitalized with P. vivax monoinfections but
not requiring ICU were consecutively recruited in a tertiary care hospital for infectious diseases to serve as a reference
population (comparators). Male sex (p=0.039), age less than five years (p=0.028), parasitemia greater than 500/mm
3
(p=0.018), and the presence of any acute (p=0.023) or chronic (p=0.017) co-morbidity were independently associated
with ICU admission. At least one of the WHO severity criteria for malaria (formerly validated for P. falciparum) was present in
23/24 (95.8%) of the patients admitted to the ICU and in 17/91 (18.7%) of controls, making these criteria a good predictor of
ICU admission (p=0.001). The only investigated criterion not associated with ICU admission was hyperbilirubinemia
(p=0.513)].
Conclusions: Our study points to the importance of P. vivax-associated severe disease in children, causing 72.5% of the
malaria admissions to pediatric ICUs. WHO severity criteria demonstrated good sensitivity in predicting severe P. vivax
infection in this small case series.
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Introduction
Malaria is one of the most important public health problems in
the world, with almost half of the world’s population at risk of
disease and an estimated 800.000 deaths annually, mainly in
children under five years of age [1]. Of the various Plasmodium
species affecting humans, Plasmodium vivax was previously consid-
ered a relatively benign infection. Recent reports, however, have
linked P. vivax to severe disease [2,3].
Malaria in Brazil has been by and large attributed to P. vivax
infection since the 1990’s [4]. In 2009, Brazil reported 308,498
cases of malaria (257,571 of P. vivax), predominantly in the
Amazon Region, representing 54.9% of all the malaria reported in
the Americas [1]. In the last two decades, the city of Manaus
(capital of the Amazonas State) has faced successive outbreaks of
malaria due to intense immigration, deforestation and unplanned
human settlements [5]. Today, with an estimated population of 2
million people, Manaus is one of three cities, which account for
25% of all reported malaria cases in Brazil. High case burdens
persist despite a well-structured public health system with universal
access to diagnosis (based on thick blood smear) and treatment.
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tPreviously, P. vivax was considered a non-fatal infection. This
perception, however, has changed in recent years, and vivax has
become recognized as a cause of severe malarial disease. Severe
clinical complications of P. vivax infection have been reported in
Brazil for the past decade, especially in Manaus [6–12]. Despite
being a significant source of morbidity, to date, no data on risk
factors of severe P. vivax disease have been published in Latin
America. The current data on predictors of clinical outcomes
originates from regions where P. falciparum and P. vivax are equally
prevalent, which could make the clinical tools inappropriate for
use in managing vivax monoinfections [13]. This lack of
prioritizing predictors of severity in P. vivax is due to the fact
that fatalities related to this species remain uncommon. According
to the official statistics, between 1998 and 2008, only 234 deaths
related to P. vivax infection were reported in the Brazilian Amazon
[4].
The first attempt to assemble the available knowledge on severe
malaria was conducted at an informal technical meeting convened
by the World Health Organization (WHO) in Kuala Lumpur,
Malaysia in 1985 [14]. The document focused on P. falciparum
infection, since, at that time, P. vivax was not thought to cause
severe disease. Throughout the years, no effort has been made to
validate or standardize specific severity criteria for vivax infections,
and current definitions seem to be heterogeneous. This absence of
consistency poses technical problems for literature review, meta-
analyses and estimation of risk factors.
Alarmingly, the incidence of severe infection appears to be
increasing [15]. Data from Manaus clearly demonstrate this
increase in a setting where uniform study criteria are applied
across time. The mechanism behind this increase remains poorly
understood as are the clinical predictors of severity and outcome.
The most robust endpoint for validating a criterion linked to
severity is death, but in vivax infections in Brazil the number of
deaths is small, which limits prognostic studies. Given this
limitation a surrogate is required to replace death. Intensive care
unit (ICU) admission could serve as this surrogate marker of
severity, in combination with well-validated severity scoring
systems that predict mortality in ICU patients. A uniform
comparator is urgently needed to help establish management
guidelines for vivax infections, especially for children under the
age of 14, which accounted for 24.3% of all malaria infections in
2010 in Manaus (SIVEP, Malaria 2010).
This study aimed to characterize all children under 14 years of
age admitted with a malaria diagnosis to an ICU in the Manaus
area from 2004 to 2009, to assess potential risk factors associated
with ICU admission (as proxy of clinical severity), and secondarily
to address the applicability of WHO falciparum severity criteria to
vivax infection, by comparing these cases to P. vivax hospitalized
children not requiring intensive care.
Methods
Ethical considerations
The review of clinical files was approved by the Ethics Review
Board (ERB) of the Fundac ¸a ˜o de Medicina Tropical Dr. Heitor Vieira
Dourado (approval number 1980), as well as by the ERB of the
Health Secretariat of Manaus and the Health Secretariat of the
Amazonas State. All data analyzed were anonymized. Since data
were obtained exclusively from clinical charts, the ERB gave a
waiver of informed consent.
Study Sites and Patient Selection
The selection of cases was performed in the city of Manaus,
capital of the Amazonas State, where Anopheles darlingi is the major
malaria vector and the annual parasite index (API) was 11.5 cases/
1,000 inhabitants, in 2009. The city has universal health assistance
for citizens (Sistema U ´nico de Sau ´de - SUS), and offers five public
pediatric ICUs (44 total available beds) and six neonatal ICUs (50
total available beds) in 11 tertiary care pediatric hospitals and
maternity wards. The infrastructure of all 11 hospitals is very
similar and staff pediatricians are from the same cooperative
society, which utilizes a single set of admission criteria and clinical
management guidelines for ICU admission (severe compromise of
respiratory and/or hemodynamic functions and/or coma). Since
every febrile patient in Manaus is subject to a thick blood smear
(TBS) and the symptoms of uncomplicated P. vivax and P.
falciparum malaria are similar, treatment seeking bias seems
unlikely. Since the access to tertiary care hospitals is relatively
easy, we assume that all critically ill patients seeking health care
were subsequently hospitalized in one of Manaus’ ICUs. Patients
in private ICUs in Manaus were excluded from this study because
the patients are generally from non-malaria endemic areas.
Patients infected with P. vivax that required an ICU admission
were compared to children of the same age range infected with P.
vivax not requiring an ICU admission but concurrently admitted to
a tertiary care center for infectious diseases (Fundac ¸a ˜o de Medicina
Tropical Dr. Heitor Vieira Dourado).
Study Design
This study is a retrospective review of clinical and laboratory
records from hospital databases. Case files for children 0–14 years
old admitted to any of the ICUs with a suspicion of malaria
between January 2004 to December 2009 were reviewed for: (1)
ICU logbooks (in which demographic data from each admitted
patient, a presumptive diagnosis at admission and a final diagnosis
at discharge are systematically registered), (2) hospital laboratory
logbooks (in which the semi-quantitative results of TBSs
performed in each hospital are systematically registered), and (3)
SIVEP-Malaria (the National Malaria Information System
available on-line, which registers results of TBSs performed in
each reporting unit such as the hospitals of interest). Cases were
included if there was evidence of malaria diagnosis by microscopy
in any of the three information systems searched. The study
enrolled only patients after 2004 because of better reliability of the
National Malaria Information System (SIVEP-Malaria) and access
to the clinical files, avoiding retrieval bias.
As comparators, clinical and laboratory data from children of
the same age group admitted between January 2009 and July 2010
to the Fundac ¸a ˜o de Medicina Tropical Dr. Heitor Vieira Dourado with a
diagnosis of malaria were retrieved electronically from the
computerized hospital records system (iDoctorH) and reviewed.
With the exception of automated full blood count, routinely
requested for all these hospitalized children, more specific
laboratory tests (such as biochemistry and arterial gas analysis)
were requested only if clinical symptoms were suggestive of
complications. As part of routine follow-up, all malaria admitted
children were reassessed in the Outpatient Clinics seven days after
discharge to guarantee adequate clinical and parasitological
follow-up.
Diagnosis of Malaria and Quantification of Parasitemia
TBSs are routinely performed for the diagnosis of malaria in
Brazil, prepared as recommended by the Walker technique [16]
and evaluated by a local microscopist. The results of peripheral
parasitemia are given using the following semi-quantitative system:
K+ (200–300 parasites/mm
3); 1+ (301–500 parasites/mm
3); 2+
(501–10,000 parasites/mm
3); 3+ (10,001–100,000 parasites/mm
3);
and 4+ (.100,001 parasites/mm
3). The cut-off to define high
Pediatric Vivax Malaria in the Intensive Care Unit
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semi-quantitative parasitemia results. All positive slides and 10%
of negative slides are routinely reviewed in a reference unit with
experienced microscopists. In case of divergence, the reviewed
result is updated in the on-line system. PCR diagnosis for malaria
was not routinely performed in these patients. Only children with
a positive TBS for Plasmodium spp. are treated according to the
Brazilian Anti-Malarial Treatment Guidelines, which recom-
mends chloroquine (25 mg/kg over 3 days)+primaquine
(0.5 mg/kg/day over 7 days) for P. vivax infection and
artemether/lumefantrine for 3 days for non-severe P. falciparum
infection. Severe P. falciparum infections are treated with parenteral
artemether or artesunate for 7 days.
Data collection and definitions
Data for each admitted individual was systematically retrieved
from the medical charts by the same member of the study team,
and included the following variables: sex, age, malarial species,
semi-quantitative parasitemia, duration of disease (in days) prior to
the admission to the ICU or ward, outcome, presence of a given
acute co-morbidity other than malaria or a chronic disease
confirmed through a reliable diagnostic method, and presence of
any WHO-defined severe malaria criteria [17]. Briefly, WHO
criteria for severe falciparum malaria validated for adults and
children include: (1) impaired consciousness or unrousable coma
(Blantyre coma scale #2 or Glasgow coma scale #10); (2)
prostration, i.e. generalized weakness such that the patient is
unable to walk or sit up without assistance; (3) failure to feed; (4)
multiple convulsions (greater than two episodes in 24 h); (5)
respiratory distress defined as the presence of deep (acidotic)
breathing or retractions; (6) circulatory collapse or shock, systolic
blood pressure ,50 mmHg (algid malaria) and/or need for
vasopressor support; (7) clinical jaundice or total bilirubin .3 mg/
dL; (8) hemoglobinuria (blackwater fever); (9) abnormal sponta-
neous bleeding (disseminated intravascular coagulation); (10)
pulmonary edema (radiological); (11) hypoglycemia (blood glucose
,40 mg/dL); (12) metabolic acidosis (plasma bicarbonate
,15 mmol/L); (13) severe anemia (Hb,5 g/dL); (14) hyperlacta-
temia (lactate .5 mmol/L); or (15) acute renal failure (serum
creatinine .3 mg/dL). Acute respiratory distress syndrome
(ARDS) was defined as acute bilateral lung infiltrates in chest X-
rays, and a PaO2:FiO2,200 mmHg. The data retrieved were
reviewed by another member of the study team and discrepancies
resolved by a third member if necessary.
In all ICUs, collection of venous blood samples for aerobic
culture and arterial blood for gas analysis was routinely carried out
on admission prior to administration of antibiotics. From all the
patients hospitalized in the ICU, the Pediatric Index of Mortality
(PIM) score was calculated with data from the first hour of
admission, based on the systolic blood pressure, pupillary reactions
to bright light, PaO2, FiO2, base excess in arterial blood, need for
mechanical ventilation at any time during the first hour in ICU,
elective admission, and presence of concomitant diagnoses [18].
Severity was defined in the presence of at least one of the
aforementioned WHO severity criteria. As blood gas analysis
samples were not systematically collected for patients not admitted
to the ICU, hyperlactatemia and metabolic acidosis were not used
to classify severity nor assessed as a risk factor associated with ICU
admission. The disease was classified as being directly caused by
plasmodial infection if no other cause was identified and no
concurrent acute or chronic diseases were confirmed.
Statistical Analyses
Data were analyzed using SPSSH version 16.0 for Windows
(SPSS Inc.H Chicago, IL, USA). Proportions of fatality were
compared by Fisher exact test (corrected by Yates’ test if
necessary); differences were considered statistically significant for
p,0.05. The crude Odds Ratio (OR) with its respective 95%
Confidence Interval (95% CI) was determined considering the
admission to ICU as the dependent variable. Logistic regression
was used for the multivariate analyses and the adjusted Odds Ratios
with 95% CI were also calculated. A multivariate logistic
regression was performed with admission to the ICU as the
outcome, using an automated backward and forward stepwise
estimation. All variables that were associated with admission to the
ICU at a significance level of p,0.10 in the univariate analysis
were included in the multivariate analysis. Statistical significance
was considered if p,0.05 in the Hosmer-Lemeshow goodness-of-
fit test.
Results
According to the official reporting systems, during the period of
2004–2009, 64,032 children 0–14 years of age were diagnosed
with malaria in Manaus (52,828 with vivax; 10,691 with
falciparum and 513 with both species). The review of logbooks
disclosed that 40 of these children were admitted with malaria to
one of the 11 pediatric or neonatal ICUs in Manaus. Thirty-four
clinical files were actually retrieved from these 40 cases (29 of
which were due to P. vivax infections), as shown in Figure 1, and six
cases were excluded because records could not be found. A rough
estimation of the risk of ICU admission per species showed similar
relative risks for P. vivax (4.7/10,000 cases) and P. falciparum (5.5/
10,000 cases), but a much higher relative risk for mixed infections
(116.9/10,000 cases).
Table 1 summarizes the clinical description of the 10 ICU cases
in which P. falciparum was diagnosed (four cases as monoinfection,
and six cases of P. falciparum/P. vivax mixed infection). Altogether,
respiratory distress (7/10) and shock (7/10) were the most
common clinical complications in these children and the case
fatality rate was 30.0% (3/10) (only two with P. falciparum
monoinfection). No other concurrent cause for ICU admission
was found in 40.0% (4/10) of the children while in the other six
children, acute and/or chronic conditions were probably acting
synergistically to produce the complications. Only one concom-
itant bacterial infection was diagnosed (Pseudomonas aeruginosa)i na
child with P. falciparum monoinfection. In all 10 patients, at least
one of the WHO criteria for severe malaria was present.
Clinical and laboratory data from the 24 children with P. vivax
monoinfection admitted to the ICU are presented in tables 2 and
3, respectively. Considering all the patients (admitted or not to the
ICU), 46/108 (,42%) patients presented with semi-quantitative
parasitemia $2+ (500–10,000 parasites/mm
3), and therefore 500
parasites/mm
3 (the lower bound of this range) was chosen as the
cut-off to define high parasitemia in our analysis, enabling similar
number of patients in both categories (low and high parasitemia).
Respiratory distress (16/24) and shock (13/24) were also the most
common complications associated with this species. Three out of
16 patients with respiratory distress had ARDS and 8/16
presented with simultaneous metabolic acidosis. No other
apparent concurrent cause for ICU admission was found in 10/
24 (41.6%) children, while in the remaining 14 children there was
evidence of the participation of acute and/or chronic conditions in
the occurrence of complications. All children were treated with
chloroquine (through nasogastric catheter when the child was
intubated), primaquine after discharge, and one or more empiric
Pediatric Vivax Malaria in the Intensive Care Unit
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with dual infection) presented positive blood cultures during the
admission (table 2). Two patients with confirmed glucose-6-
phosphate dehydrogenase (G6PD) deficiency experienced severe
hemolysis, hemoglobinuria and acute renal failure after the
beginning of primaquine (all started with hemoglobinuria during
the second or third day of treatment). All the patients who
developed shock syndrome required administration of vasoactive
amines. With the exception of one patient with a previous
diagnosis of idiopathic thrombocytopenic purpura (ITP), who
presented with moderate bleeding and was admitted to the ICU as
a result, all remaining 23 patients had one or more WHO severity
criteria for malaria. All the patients demonstrated a TBS negative
for Plasmodium spp. following chloroquine treatment.
Table 4 summarizes the results of the univariate and
multivariate logistic regression evaluating risk factors associated
with ICU admission. Males [OR=5.90 (95% CI=1.28–34.25);
(p=0.039)], age ,5 years [OR=6.36 (95% CI=2.67–13.63);
(p=0.028)], peripheral parasitemia greater than 500/mm
3
[OR=4.94 (95% CI=1.31–18.63); (p=0.018)], the presence of
acute [OR=8.13 (95% CI=1.33–49.81); (p=0.023)] and/or
chronic co-morbidities [OR=6.02 (95% CI=1.38–26.35);
(p=0.017)] were all independently associated with the risk of
developing life-threatening P. vivax monoinfection requiring
admission to an ICU. None of the children not admitted to the
ICU developed severe disease after their discharge, as reviewed in
their electronic files from follow-up visits in the outpatient clinics.
Table 5 compares ICU admitted P. vivax monoinfections with
hospitalized P. vivax patients not requiring ICU admission. Of all
variables assessed for both groups, the odds of being admitted to
the ICU increased in patients fulfilling at least one WHO severity
criterion, particularly in those with severe anemia or coma. The
mean of the PIM, a validated score that parallels bad prognosis in
pediatric ICUs, was higher in children with shock and coma. P.
falciparum or P. falciparum/P. vivax infected children (30.0%) died
more frequently than those infected with P. vivax monoinfection
(8.3%), but this difference was not significant (Yate’s corrected
Fisher’s exact test; p=0.138). P. falciparum monoinfection showed
higher fatality (2/4; 50.0%) when compared to P. vivax
monoinfection (2/24; 8.6%), but this difference likewise was not
significant (p=0.086).
Discussion
This study showed that in Manaus most of the malaria-
associated hospitalizations in ICUs were related to P. vivax during
the period of study, confirming the public health impact of this
infection [19–20]. Male sex, age less than five years, parasitemia
greater than 500/mm
3, and the presence of any acute or chronic
co-morbidity were independently associated with ICU admission.
At least one of the WHO severity criteria for malaria (formerly
validated for P. falciparum infection only) was present in most of the
patients admitted to the ICU. WHO severity criteria may also
serve as predictors of severity for P. vivax patients. Further studies,
however, are needed to confirm this finding considering the small
number of cases presented in our series.
A significant male sex predominance among children admitted
to the ICU in our study contrasts with data from Indonesia and
India, where the female sex was associated with severity in vivax
infection [3,21]. One possible explanation of this difference is the
heterogeneous age range of infected children in these continents.
Similar to what was observed by Tjitra and colleagues in Papua,
Indonesia [3], respiratory distress, present in two-thirds of patients
in our series, was the most frequent complication among patients
admitted to the ICU with P. vivax infection, and had a particularly
poor prognosis. In P. falciparum malaria, respiratory distress arises
secondary to either primary pulmonary pathology mediated by
sequestration of parasitized erythrocytes in the lung microvascu-
lature or from the drive to compensate metabolic acidosis. For P.
vivax malaria, however, the pathophysiology behind respiratory
distress is not well understood. Studies performed in uncompli-
cated vivax patients suggest that progressive alveolar-capillary
Figure 1. Flow diagram of patients admitted to ICUs enrolled in the analysis.
doi:10.1371/journal.pone.0035406.g001
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35406dysfunction occurs after treatment, and this inflammatory
response is proportional to initial parasite burden in P. vivax
[22]. More recently, ex vivo adhesion of P. vivax-parasitized red
blood cells to human lung endothelial cells was demonstrated for
the first time [23], suggesting that cytoadhesion could play a role
in the pathogenesis of this disease. Although, in a patient who died
of ARDS, histopathological analysis did not show any evidence of
cythoadhesion [24]. Patient outcomes in this series support the
hypothesis of a primary pulmonary lesion driving the respiratory
clinical manifestations, complicated by the presence of concom-
itant metabolic acidosis or severe anemia. Half of the 16 patients
with respiratory distress had concomitant metabolic acidosis, but
only 2 had severe anemia simultaneously. Pneumonia is another
confounding diagnosis of respiratory distress, and in all the
Table 3. Detailed laboratorial information from 24 children 0–14 years old, at the moment of admission to any of the pediatric or
neonatal ICUs in Manaus, from 2004 to 2009, with parasitological diagnosis of P. vivax.
Patient Hb (g/dL)
Leukocyte/
mm
3 Platelets/mm
3 AST (mg/dL) ALT (mg/dL)
Creatinin
(mg/dL)
Total bilirubin
(mg/dL)
Glucose
(mg/dL)
1 9.1 18,600 49,000 286 253 0.7 0.9 90
2 2.8 25,600 34,000 160 111 0.6 4.3 55
3 8.5 6,400 161,000 23 15 0.6 0.6 70
4 8.5 19,300 180,000 73 22 1.9 0.3 304
5 10.4 9,000 378,000 20 30 1.0 1.0 199
6 2.5 28,600 13,000 83 48 0.6 8.3 59
7 5.0 22,500 16,000 961 1400 2.7 1.0 64
8 9.5 13,700 113,000 15 23 0.8 1.0 28
9 8.3 30,100 207,000 17 19 0.5 1.0 64
10 8.6 12,700 129,000 23 27 0.8 6.7 88
11 7.9 57,700 93,000 34 45 1.1 1.0 67
12 5.0 12,100 170,000 222 53 7.5 2.7 42
13 5.9 10,100 174,000 56 10 0.4 1.0 63
14 4.2 18,700 303,000 29 26 7.1 1.4 39
15 8.8 4,600 78,000 30 28 0.4 1.0 38
16 6.5 16,600 611,000 25 15 0.9 1.0 75
17 9.1 16,800 196,000 22 29 0.4 1.0 90
18 5.0 31,500 76,000 34 43 0.4 1.0 67
19 7.4 8,500 190,000 133 46 0.3 2.8 98
20 3.3 31,600 19,000 30 45 0.8 1.6 70
21 6.2 29,600 6,000 20 17 0.9 1.0 88
22 8.7 19,600 104,000 159 64 0.7 1.0 52
23 7.3 11,200 69,000 34 50 1.0 1.0 70
24 7.4 2,100 15,000 45 23 1.0 24.2 101
Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotrasferase.
doi:10.1371/journal.pone.0035406.t003
Table 4. Univariate and multivariate (logistic regression) analysis of factors associated to the admission in the ICUs of children 0–
14 years old with P. vivax infection, in Manaus, from 2004 to 2009.
Cases admitted to
the ICU n/N (%)
Patients not requiring
admission to the ICU
n/N (%)
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI) p-value
Male sex 17/24 (70.8) 53/91 (58.2) 1.91 (0.92–5.71) 5.90 (1.28–34.25) 0.039
Age (,5 years) 20/24 (83.3) 25/91 (27.5) 4.64 (2.05–7.65) 6.36 (2.67–13.63) 0.028
Peripheral parasitemia (.500 parasites/
mm
3)
14/19 (73.6) 32/89 (36.0) 4.99 (1.65–15.12) 4.94 (1.31–18.63) 0.018
Time of acute disease prior to treatment
(.7 days)
8/24 (33.3) 22/91 (24.2) 1.57 (0.60–4.16) 3.39 (0.81–14.10) 0.093
Presence of any chronic disease 10/24 (41.7) 9/91 (9.9) 6.50 (2.25–18.86) 6.02 (1.38–26.35) 0.017
Presence of any other acute co-morbidity 9/24 (37.5) 7/91 (7.7) 7.20 (2.33–22.30) 8.13 (1.33–49.81) 0.023
doi:10.1371/journal.pone.0035406.t004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35406children in the present report antibiotics were prescribed
empirically.
The occurrence of severe anemia also paralleled data from
other endemic areas [25], and was consistent with previous data
published from Manaus [11,26]. Further corroborating data from
Indonesia [27], we observed that 5 out of 6 children under 3
months of age presented severe anemia, confirming P. vivax as a
cause of severe morbidity in the early infancy. Severe anemia can
also be seen, not triggered by the parasite itself, in patients with
G6PD deficiency, as a complication of the use of primaquine for
the radical cure of hypnozoites, as observed in three patients
described here (two with pure P. vivax and one with mixed
infection). If followed by acute renal failure (ARF), it constitutes
the syndromic presentation of blackwater fever [28]. Acute renal
failure was mostly related to acute hemolysis in patients with
G6PD deficiency. The possibility of concomitant P. malariae
infection, a species known to cause acute or delayed renal
complications seems highly improbable, as this species is not
detected in Manaus [33]. G6PD deficiency seems to be frequent in
Brazilian malaria-endemic areas, where it is not routinely screened
before the prescription of antimalarials. The prevalence of the A
2
variant among males has been estimated at 3% [29], and a
number of hospitalizations due to this complication have been
reported [30]. If G6PD deficiency is not ruled out in epidemio-
logical studies focusing on vivax-related anemia, this complication
triggered by the parasite per se could be falsely overestimated.
Circulatory collapse (algid malaria) associated with P. vivax
infection was both frequent and severe, requiring the use of
vasopressors, with or without a confirmed positive blood culture
for aerobes. Even for P. falciparum malaria, the etiology of this
complication is uncertain and the potential role of septic shock as a
concomitant entity has been proposed [31]. In such cases
therefore, blood cultures are mandatory to rule out bacterial co-
infections, which may be related to severity and consequently to
ICU hospitalization.
The presence of hyperbilirubinemia is becoming recognized
recently as an inappropriate criterion of severe disease if found in
isolation [32]. In our data this laboratory finding was not
predictive of ICU hospitalization [OR=1,45 (CI=0,42–5,05),
p=0,513]. Jaundice detected on a routine physical exam,
however, could still be used as a warning sign of severity, given
that in 3/4 cases jaundice was accompanied by another severity
criterion. As serology for the common viral hepatitis in this region
was not requested, it is difficult to ascertain whether such episodes
were primarily caused by P. vivax per se or resulted from a
concomitant liver infection.
Coma was also reported in our series, but in 3 out of 5 children
with coma, additional explanations other than cerebral malaria
could be found, such as viral encephalitis in one, and
decompensation of previous neurological sequelae in two. In one
patient hypoglycemia could also be a superimposed factor.
Cerebral vivax malaria actually seems to be more common in
children [34], but the possibility of other infectious diseases of the
central nervous system has to be taken into consideration given the
low prevalence of cerebral malaria in vivax infection [35].
It is noteworthy that acute or chronic co-morbidities were
detected in 58% (14/24) of the patients with P. vivax. This was also
observed in an almost identical proportion (6/10) of P. falciparum
patients, which leads to the conclusion that the presence of co-
morbidities may contribute to or facilitate the appearance of
complications in all malaria. Importantly, this aspect seems to
have been specially underreported in prospective studies on vivax
severity [3]. Recent data suggests that P.vivax-triggered anemia
could be related to parvovirus B19 infection [36]. In our series,
rotavirus infection was found among ICU-admitted P. vivax (4
cases) and P. falciparum (2 cases) children. Despite the lack of local
data on rotavirus infection, the worldwide-recognized increased
severity in those less than 5 years of age could in part explain the
younger age of the ICU hospitalized children. Furthermore, in our
children, septic shock with confirmed bacteremia was observed in
three cases. In Mozambique, the systematic performance of blood
cultures on hospital admissions showed that a positive culture for
aerobes in children with malaria was associated with an increased
risk of death [37]. Therefore, a predisposition to malarial infection
in the setting of other bacterial infections may apply to all
Plasmodium species. The finding of four malnourished children
among vivax cases admitted to the ICU does not seem negligible,
and should be taken into consideration as a potential confounding
factor when severity frequencies are compared across the world
[38]. Although P. vivax can surely independently cause severe or
even life threatening episodes in adults and children, the relative
importance of co-morbidities or other chronic existing conditions
Table 5. Descriptive data and univariate analysis of P. vivax monoinfection cases admitted to the ICU versus patients not requiring
ICU admission, according to the WHO type of severity.
Cases admitted to
the ICU n/N (%)
Patients not requiring
ICU admission n/N (%) Odds ratio (95% CI) p-value
PIM Score (%)
of cases (Mean
± SD)
WHO criteria for malaria severity 23/24 (95.8) 17/91 (18.7) 100.11 (12.60–793.60) ,0.001 16.2615.6
Respiratory distress 16/24 (66.7) 0/91 (0.0) - - 18.4615.7
Shock (algid malaria) 13/24 (54.2) 0/91 (0.0) - - 23.3617.0
Metabolic acidosis 10/24 (41.6) - - - 16.0612.3
Severe anemia 7/24 (29.2) 5/91 (5.5) 7.08 (2.00–24.97) 0.003 11.068.5
Coma 5/24 (20.8) 2/91 (2.2) 11.71 (2.11–64.94) ,0.001 37.2618.1
Hyperbilirrubinemia 4/24 (16.7) 11/91 (12.1) 1.45 (0.42–5.05) 0.513 15.0611.8
Hypoglycemia 3/24 (12.5) 0/91 (0.0) - - 17.1620.4
Acute renal failure (ARF) due to
hemoglobinuria
2/24 (8.3) 0/91 (0.0) - - 3.261.1
Death 2/24 (8.3) 0/91 (0.0) - - 50.866.9
doi:10.1371/journal.pone.0035406.t005
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disregarded.
Despite the WHO recommendation to treat patients with severe
P. vivax malaria as patients with severe P. falciparum/P. vivax
malaria, due to the possibility of submicroscopic parasitemia of the
first species, the Brazilian Guidelines for Antimalarial Treatment
have only recently changed. During the study period of the present
study, chloroquine was prescribed to all patients. Resistance to
chloroquine was described for the first time in Latin America in
Manaus [39], and more recent data suggest that in vivo resistance
in this locality is estimated at 10% [40]. However the resistance
does not seem to be disseminated throughout the country [41],
and the first line treatment for P. vivax is still chloroquine.
Ecological studies suggest that severity in vivax infection could be
related to chloroquine-resistance [42]. These and previous data,
however, show a good response to chloroquine in severe patients,
and suggest that in the Brazilian Amazon this association is not
well understood [11].
The fatality rate among P. vivax patients hospitalized in the ICU
(8.3%) was not insignificant, even in the Brazilian scenario where
diagnosis and treatment of malaria are free and universally
available. These numbers could be far larger, however, if a
reasonably established health system with tertiary care facilities is
not in place. Our small sample was unable to show that P.
falciparum children died more frequently than those infected with P.
vivax. Actually data from other settings point to a similar fatality
rate between the two species [21,43]. From our data it is possible
to detect a high risk of ICU admission among children with mixed
infections, however this finding needs to be confirmed in other
similar settings in Latin America. PIM score predicted mortality
relatively well and its use should be emphasized in future similar
pediatric studies.
An important limitation of this study is its retrospective design,
and all analyzed information is based on the available registration
in clinical charts. Besides that, the absence of PCR confirmation of
malarial infections is an additional limitation. Species-specific
PCR increases the diagnostic accuracy and can detect submicro-
scopic infections that may have been disregarded only after
standard microscopy. It is possible therefore, that some of our
assumed P. vivax monoinfections may in fact be mixed cases.
Although possible, this seems unlikely, as a preliminary analysis
from our laboratory shows that only 5% of the positive TBSs for P.
vivax identify mixed infections, based on real-time PCR (data not
shown). Another limitation is the lack of information on total
number of patients hospitalized due to malaria in Manaus in the
period.
In the present study we showed that, in absolute numbers, P.
vivax infection was responsible for most of the ICU admissions of
children 0–14 years old due to severe malaria (despite of similar
proportional numbers when compared to P. falciparum infections
reported), and that the clinical complications were very similar to
those seen in P. falciparum in this same endemic area. Despite the
fact that peripheral parasitemia greater than 500/mm
3 was
associated with ICU hospitalization, the positive predictive value
of this cut-off for predicting need for ICU admission is extremely
low, given the tiny fraction of malaria cases requiring ICU in the
general population. Severe vivax patients should also trigger the
routine screening of additional infectious diseases in the daily
practice in the tropics. From the public health perspective,
decision-makers from national malaria programs should re-
orientate clinical management algorithms in order to improve
treatment, diminish the burden of hospitalization, decrease costs
and reduce malaria-associated mortality.
From the basic science perspective, pathogenesis studies in
severe vivax should carefully rule out other diseases, which may
alter the immune response [44]. Definitely respiratory distress,
shock and anemia are major complications associated with P. vivax
infection, for which mechanisms are poorly understood even in the
case of severe P. falciparum. More studies are needed to evaluate the
applicability of these findings in other age groups. Due to the fact
that studies on the clinical aspects and biology of P. vivax have been
neglected during most of the 20
th century, the large knowledge
gaps regarding this parasite [45] may pose challenges for future
malaria eradication plans [46].
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